MedPage Today6d
First Omalizumab Biosimilar Approved
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any ...
Rolling Out6d
New drug outperforms therapy for severe food allergies
A landmark clinical trial has discovered that omalizumab, marketed as Xolair, provides more effective treatment for multiple food allergies than the current standard approach of oral immunotherapy ...
Healio9d
FDA approves omalizumab biosimilar Omlyclo
Omlyclo is the first interchangeable biosimilar to omalizumab (Xolair; Genentech, Novartis). Omlyclo was approved to treat the same conditions as Xolair. The FDA approved Celltrion’s omalizumab ...
Pharmabiz11d
Omalizumab treats multi-food allergy better than oral immunotherapy: Study
A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small ...
technologynetworks13d
Omalizumab Treats Food Allergy More Effectively Than Immunotherapy
New research, led by Johns Hopkins Children’s Center investigators and sponsored by the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID), finds that ...
Healio12d
Patients introduce allergens into their diets after using omalizumab
SAN DIEGO — Patients with multiple food allergies introduced allergens into their diets after using omalizumab, researchers reported at the 2025 American Academy of Allergy, Asthma & Immunology ...
Monthly Prescribing Reference13d
Omalizumab vs OIT: Head-to-Head Study Compares Food Allergy Treatments
Thirty-six percent of patients treated with omalizumab were able to tolerate 2000mg of peanut protein and 2 other food allergens without experiencing an allergic reaction compared with 19% of OIT ...
MedPage Today12d
Omalizumab Superior to Oral Immunotherapy for Kids With Multi-Food Allergy
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among ...
Morningstar6d
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar ...
U.S. News & World Report13d
Injectable Drug Resolves Dangerous Food Allergies In One-Third Of Kids
In all, 36% of children treated with omalizumab (Xolair) for a year successfully ate full servings of allergy-triggering foods, according to phase 2 trial results presented Sunday at a meeting of ...
Yahoo Finance13d
Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies
Xolair is the only US FDA-approved medicine to reduce allergic reactions in children and adults with one or more food allergies Basel, 2 March 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ...